Reata’s lead pivotal programs are aimed at the development and commercialization of therapies for Alport syndrome (AS), Friedreich’s ataxia (FA), connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), and autosomal dominant polycystic kidney disease (ADPKD). Ongoing inflammation, mitochondrial dysfunction, and oxidative stress are implicated in these diverse, chronic diseases for which there are few or no approved therapies.
Mitochondria play a critical role in balancing cellular energy production and the inflammatory response. Mitochondrial dysfunction occurs when cellular energy production is impaired in favor of production of proinflammatory reactive oxygen species (ROS). Therefore, mitochondrial dysfunction can lead to tissue fibrosis, organ remodeling, or other organ damage.
Autosomal Dominant Polycystic Kidney Disease (ADPKD) (coming soon)